(Press-News.org) (San Diego, Calif.--September 8, 2024, 10:05 a.m. PCT) – New data presented today demonstrate that TROP2 expression as measured by quantitative continuous scoring (QCS), a computational pathology approach, is a promising predictor of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated with the TROP2 antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). The data showed that patients with TROP2 positivity, as determined by QCS, experienced improved efficacy with Dato-DXd compared to patients receiving docetaxel in the TROPION-Lung01 phase III trial.
The study was presented today at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer by Dr. Marina Chiara Garassino, from The University of Chicago.
Dato-DXd is a TROP2-directed ADC designed with a unique plasma-stable linker that necessitates active internalization for effective payload release. Traditional methods of assessing TROP2 expression through visual scoring of immunohistochemical (IHC) assays have not been predictive of responses to TROP2-directed ADCs in NSCLC patients. To address this gap, the authors hypothesized that a more precise, quantitative measurement of TROP2 expression both on the cell membrane and in the cytoplasm would better predict therapeutic responses to Dato-DXd.
This analysis utilized digitalized TROP2 IHC-stained whole-slide images (WSI) from NSCLC patients to develop the QCS model. This deep learning algorithm, trained on pathologists' annotations, identifies tumor areas and cellular compartments (membrane and cytoplasm) within the WSI. The QCS model calculates TROP2 expression in the membrane relative to the cytoplasm of tumor cells, producing a normalized membrane ratio (NMR). Tumors were classified as TROP2 QCS-NMR+ if most tumor cells exhibited an NMR below a predetermined value.
The QCS-NMR was optimized for progression-free survival (PFS) in the biomarker-evaluable subgroup of nonsquamous (NSQ) NSCLC patients without actionable genomic alterations (non-AGA) in TROPION-Lung01, which compared Dato-DXd to docetaxel in second-line or later advanced or metastatic NSCLC. Clinical outcomes were assessed across all biomarker-evaluable patients.
Out of 604 patients randomized in TROPION-Lung01, 352 were biomarker-evaluable, with 221 in the NSQ/non-AGA subgroup. The baseline characteristics were consistent between randomized and biomarker-evaluable populations, showing similar overall PFS outcomes. Among the evaluable patients, 63% were classified as TROP2 QCS-NMR+. The highest prevalence of TROP2 QCS-NMR+ was observed in the NSQ/AGA subgroup (75%), followed by NSQ/non-AGA (63%) and squamous (SQ) (43%) subgroups.
Data indicated that the objective response rate (ORR) was higher and median PFS was longer with Dato-DXd compared to docetaxel in TROP2 QCS-NMR+ subgroups. The rates of overall and grade 3+ adverse events were similar regardless of TROP2 QCS-NMR status.
“It is important that research identifies how to optimize treatment options for patients with NSCLC. This exploratory analysis is going in this direction and reveals that Dato-DXd exhibits robust efficacy in patients with TROP2 QCS-NMR+ advanced non-small cell lung cancer, in the nonsquamous, non-AGA subgroup,” Dr. Garassino reported.
The QCS-measured TROP2 NMR shows potential as a predictive biomarker for Dato-DXd response. Further studies are underway to validate this biomarker in the first-line advanced or metastatic NSCLC setting.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2024.iaslc.org.
END
Normalized membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes in TROPION-Lung 01
2024-09-08
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive advanced NSCLC in HARMONi-2 study
2024-09-08
(San Diego, Calif--September 8, 2024, 8:30 a.m.) — Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer. The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer.
The HARMONi-2 study randomized 398 patients ...
NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC -- Data builds on AEGEAN study research
2024-09-08
(San Diego, Calif. September 8, 2024 10:05 a.m. PCT) – Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens.
The data was presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer by Dr. Tina Cascone, from The University of Texas MD Anderson Cancer Center in Houston.
“The findings highlight the potential of combining durvalumab with novel anticancer agents to build on what we have learned in the perioperative immunotherapy arena for patients with ...
Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence
2024-09-08
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
For the study, researchers compared health outcomes among 147 participants in the CheckMate 816 study — in which patients received three cycles of the immunotherapy nivolumab plus chemotherapy before surgery (neoadjuvant) — with results of 139 participants in the CheckMate 77T trial, in which patients received up to four cycles of nivolumab plus chemotherapy ...
Young vapers perform worse in exercise testing
2024-09-08
Young people who vape perform worse than non-vapers in tests designed to measure their capacity for exercise, according to a study presented at the European Respiratory Society (ERS) Congress in Vienna, Austria [1]. The research also showed that the performance of young vapers was similar to that of young smokers.
The study adds to growing evidence that long-term use of vaping is harmful and challenges the idea that vaping could be a healthier alternative to smoking.
The research was presented by Dr Azmy Faisal, senior lecturer in cardiorespiratory physiology in the department of sport and exercise sciences at Manchester Metropolitan ...
Medical clowns shorten hospital stays for children with pneumonia
2024-09-08
Spending time with a medical clown can shorten the length of hospital stay for children with pneumonia, according to research presented at the European Respiratory Society (ERS) Congress in Vienna, Austria [1]. They can also reduce the duration of intravenous antibiotic use.
The study was presented by Dr Karin Yaacoby-Bianu from Carmel Medical Center and the Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
She explains: “Medical clowns undergo specific training to work in hospitals. They have been shown to reduce ...
New report finds the changing nature of work provides new opportunities for workplace gender equality
2024-09-08
A new research report released today has identified an important shift in how employees choose to engage in the workforce, as they increasingly seek flexibility and opportunities to tailor work schedules and locations to their needs.
The ninth report in the Gender Equity Insights Series from the Bankwest Curtin Economics Centre (BCEC) and the Workplace Gender Equality Agency (WGEA) provides an in-depth analysis of the evolving nature of part-time work and implications of this change for the future of work in Australia.
Despite Australia having one of the highest shares of part-time employment across OECD countries, ...
Insulin resistance is linked to over 30 diseases – and to early death in women, study of people in the UK finds
2024-09-08
Insulin resistance is associated with 31 different diseases and, in women, is also linked to higher odds of an early death, a study of data on hundreds of thousands of people in the UK being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), has found.
The conference will hear that there is compelling evidence of links between insulin resistance and conditions as diverse as Parkinson’s diease, gout and sciatica.
Insulin resistance, when the body’s cells don’t respond properly to insulin and can’t easily take up glucose from blood, is a key feature ...
Innovative semaglutide hydrogel could reduce diabetes shots to once a month
2024-09-08
French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year’s annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
“Glucagon-like peptide-1 agonist (GLP-1) drugs have transformed type 2 diabetes care, but weekly injections can be burdensome for patients. A single shot a month could make it much easier for people living with diabetes or obesity to stick to their drug regimens, improving quality of life and reducing side effects and diabetes complications,” ...
Weight loss could reduce the risk of severe infections in people with diabetes, UK research suggests
2024-09-08
Weight loss interventions could reduce the risk of severe cases of flu and other infections in people with diabetes, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) suggests.
The study, from Rhian Hopkins and Ethan de Villiers, of the University of Exeter Medical School, University of Exeter, Exeter, UK, found evidence to suggest that a higher BMI is a cause of severe infections.
In contrast, there was no evidence that mild hyperglycamia contributes ...
Long-term exposure to air pollution and a lack of green space increases the risk of hospitalization for respiratory conditions
2024-09-08
Long-term exposure to air pollution and a lack of access to green spaces increases the risk of hospitalisation for respiratory conditions, according to a study presented at the European Respiratory Society (ERS) Congress in Vienna, Austria [1].
Traffic-related air pollution is also strongly linked to the progression from asthma to asthma-COPD, according to a second study also presented at the ERS Congress [2].
Previous research has linked air pollution to an increase in respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), and ...